Ecraid becomes the newest member of the PrIMAVeRa Consortium
- danielreem
- 6 minutes ago
- 2 min read
19 November 2025
The PrIMAVeRa consortium is pleased to welcome its newest member: the European Clinical Research Alliance on Infectious Diseases (Ecraid). Established in 2022, Ecraid is the first European network offering a single point of access to a pan-European clinical research network for infectious diseases. Its mission is centred on improving clinical evidence for infectious diseases and antimicrobial resistance. As part of the project, Ecraid will provide access to valuable data, as well as the scientific analysis of the data. This will help refine and train the mathematical models being developed to demonstrate the impact of vaccines and monoclonal antibodies on antimicrobial resistance.
The value of this addition to the consortium lies predominantly in the data that will become available to the project’s mathematical modellers. Ecraid oversees two perpetual observational studies (POS) on complicated urinary tract infections and ventilator-associated pneumonia, with data from more than 12,000 enrolled patients at the time of press. The ample data from these studies will cover previously identified data gaps on infection outcomes, stratified according to antibiotic susceptibilities and implemented therapies, duration of treatments and associated hospital resource consumption, and other categories of particular interest to those modelling the cost-effectiveness of various interventions.
PrIMAVeRa partners extend a warm welcome to their newest collaborators, and look forward to the benefit this will bring the project, as well as the reinforcements that this addition represents in the ongoing fight against AMR.
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA. www.imi.europa.eu
This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
